Best Epitalon Providers in 2026 — Ranked & Reviewed

Epitalon (also spelled epithalon) is a synthetic four-amino-acid peptide based on epithalamin, an extract originally isolated from the pineal gland, and it's one of the more studied longevity peptides on activating telomerase, the enzyme that rebuilds the protective caps on chromosomes. In lab-grown human cell lines, it has extended cells past their normal division limit, and older-adult human trials run in Russia reported longer telomeres and lower mortality over long-term follow-up — but that research comes from decades of Russian institutional studies without independent validation elsewhere, and there's no equivalent Western clinical-trial evidence. No compounding pharmacy can currently sell it lawfully in the US either. See below for the current status.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

Why there’s no ranking here yet

On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding Epitalon to the Section 503A Bulk Drug Substances List. That vote is a recommendation only; the FDA and HHS still need to formally act on it before any compounding pharmacy can lawfully sell Epitalon. We're tracking the decision and will rank compliant providers here the moment one exists.

We’d rather show nothing than list a provider who can’t legally sell this yet. We’re tracking the FDA’s decision and will rank compliant providers here the moment one exists.

How we rank & what counts as “legit”

Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.

Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].

Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].

Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Frequently Asked Questions

Each provider is evaluated across six weighted dimensions: Value (25%), Effectiveness (25%), User Experience (15%), Trust & Safety (15%), Accessibility (10%), and Support (10%). We research publicly available information, user reviews, clinical evidence, and pricing data, then compute a weighted overall score out of 10.
Each provider's score is computed independently using the six-dimension methodology, and a commercial relationship never changes a provider's underlying score — you can see every provider's full score on its card. Some providers have affiliate agreements with us, meaning we earn a commission if you click through and make a purchase. On our highest-commercial-intent lists — including the semaglutide, tirzepatide, compounded and cheapest molecule lists, the weight-loss injection and shot lists, and the fitness-app list — we feature affiliate partners in the top positions; on every other list the order follows the score (or, for the cheapest lists, the lowest price) directly. This placement is disclosed here and on our methodology and affiliate-disclosure pages.
Sources & methodology — as of September 2026
  1. 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  5. 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  8. 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  9. 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  10. 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
  11. 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Related Rankings